Table 6 Baseline demographic and clinical features of the independent clinical plasma cohort used for biomarker validation

From: A machine learning–enabled blood transcriptomic signature for digital diagnosis and subtyping of Alzheimer’s disease

Variable

NC (n = 180)

AD (n = 270)

aMCI(n = 90)

P

Gender: Female

82 (45.6%)

145 (53.7%)

46 (51.1%)

0.237

Gender: Male

98 (54.4%)

125 (46.3%)

44 (48.9%)

0.237

Age (mean ± SD)

76.77 ± 7.48

79.93 ± 7.33

79.60 ± 4.90

<0.001

MMSE (mean ± SD)

29.32 ± 0.89

15.89 ± 7.20

26.38 ± 0.72

<0.001

PSQI (mean ± SD)

4.55 ± 4.83

7.07 ± 4.12

6.20 ± 5.38

<0.001

NRS2002 (mean ± SD)

0.57 ± 1.10

1.02 ± 1.49

1.00 ± 1.60

0.0739

SDS (mean ± SD)

22.47 ± 13.47

24.30 ± 9.65

26.68 ± 13.13

0.135

SAS (mean ± SD)

22.23 ± 13.48

26.97 ± 15.53

26.04 ± 13.07

0.0739

FRAIL (mean ± SD)

1.18 ± 1.39

2.84 ± 1.42

1.62 ± 1.53

<0.001

ADL (mean ± SD)

6.71 ± 2.10

62.60 ± 26.14

33.60 ± 19.85

<0.001

  1. Data are presented as mean ± standard deviation (SD) or n (%). P values were calculated using the chi-square test for categorical variables and one-way analysis of variance (ANOVA).
  2. NC normal controls, AD Alzheimer’s disease, aMCI amnestic mild cognitive impairment, MMSE Mini-Mental State Examination, PSQI Pittsburgh Sleep Quality Index, NRS2002 Nutritional Risk Screening 2002, SDS Self-Rating Depression Scale, SAS Self-Rating Anxiety Scale, FRAIL Fatigue-Resistance-Ambulation-Illness-Loss scale, ADL Activities of Daily Living.
Back to article page